Trial Information
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Inclusion Criteria:
- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by
the investigator to prescribe Nexavar® under Taiwan reimbursement guideline
- Patients must have a life expectancy of at least 8 weeks
Exclusion Criteria:
- Exclusion criteria must follow the approved local product information.
- Patients were lost to follow-up if no follow-up visit and no final assessment of
Nexavar® was documented.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of number of adverse events)
Outcome Time Frame:
After one year
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Taiwan: Institutional Review Board
Study ID:
15242
NCT ID:
NCT01195649
Start Date:
December 2010
Completion Date:
March 2015
Related Keywords:
- Carcinoma, Renal Cell
- Carcinoma
- Carcinoma, Renal Cell